Lyme borreliosis: New approach for developing targeted therapy

Posted by Michael Jannicelli | Oct 24, 2024 | Uncategorized | 0 |

Lyme borreliosis is the most common tick-borne infectious disease in Europe. Up to 70,000 new cases are estimated each year in Austria alone. The bacterial infection can cause lasting health problems for patients. A research team has made significant progress in understanding the mechanism of infection and identified a potential way forward for the development of targeted therapies that do not rely on antibiotics.

About The Author

Michael Jannicelli

Michael Jannicelli - "A PROVEN BUSINESS FIRESTARTER & BRANDING GENIUS" a true natural born Trendsetter. • Created over 100 products under 3 brands, sold in 30+ countries worldwide and influencing youth across the globe. • Featured in Forbes magazine +over 100 print publications, television talk shows, major motion pictures and national radio stations. • Co-founder and VP of Bliss beverage USA and President/co-founder of Socko International - fastest growing privately held beverage company in US (Forbes) with Hogan Energy & Raw Energy WWE. • Co-founder of Throwdown Industries (2003) - leading brand in multibillion dollar Impact/Action Sports Market (products designed for superior MN • Diagnosed with auto-immune diseases aged 13; using his experience to help others and promote a positive message while developing edgy products to benefit people with chronic illness.